Study on the antiviral activity of San Huang Yi Gan Capsule against hepatitis B virus with seropharmacological method
© Xu et al.; licensee BioMed Central Ltd. 2013
Received: 10 July 2012
Accepted: 24 September 2013
Published: 27 September 2013
Seropharmacology arising recently is a novel method of in vitro pharmacological study on Chinese herb using drug-containing animal serum. As seropharmacology possesses the advantages of experiments in vitro and in vivo, it is increasingly applied in pharmacological research on Chinese medicine. However, some issues of seropharmacology remain controversial and need to be clearly defined. San Huang Yi Gan Capsule (SHYGC) is a Chinese herbal formula with antiviral property against hepatitis B virus (HBV), but little is known about the mechanism underlying its anti-HBV activity. The aim of the present study was to elucidate the action mechanism of SHYGC using seropharmacological method and systematically address the methodology of preparing drug-containing serum.
New Zealand rabbits were orally administrated SHYGC with various regimens, followed by preparation of SHYGC-containing rabbit sera with a variety of methods. After HBV-producing HepG2 2.2.15 cells were treated with SHYGC-containing sera or entecavir for 9 days, the levels of hepatitis B surface antigen (HBsAg) and HBV DNA and the activity of DNA Polymerase were determined in HepG2 2.2.15 cells-conditioned media.
An optimally standardized method of preparing drug-containing serum was raised for seropharmacology, with which SHYGC was demonstrated to suppress HBsAg expression, HBV DNA replication and DNA Polymerase activity in a dose-dependent fashion.
This seropharmacological study shows SHYGC is a potentially powerful anti-HBV agent. Additionally, seropharmacology is a promising pharmacological method with a broad range of advantages, and it can be widely used in biomedical research, if combined with pharmacokinetics.
KeywordsEntecavir Hepatitis B virus San Huang Yi Gan capsule Seropharmacology
Seropharmacology is a novel method arising over the relatively recent years for pharmacological study on Chinese materia medica in vitro using drug-containing serum [1–5]. The essence of seropharmacology is administration of drug to experimental animal (rabbit, rat or mouse), followed by harvest of animal blood and conduction of in vitro pharmacological experiment with the drug-containing animal serum. This pharmacological method has the same advantages as the in vitro experiment, for instance, convenient control of experimental condition and exclusion of interference by internal factors, which facilitate in-depth study on the action mechanism of drug. More importantly, seropharmacology reflects the internal process (absorption, distribution, metabolism and excretion) of drug in the body, as the drug contained in the animal serum is in the form of bioactive metabolite with the truly pharmacological potency of interest after internal biotransformation. By building a bridge between the experiments in vitro and in vivo, seropharmacology is a perfect combination of the two experimental systems. As Chinese herb generally features numerous components, complex metabolism and multiple drug targets, it is an arduous task to clarify each ingredient. On the other hand, single component can not represent the whole herb in respect of efficacy. Therefore, seropharmacology is quite suitable to the study on Chinese medicine, and it is increasingly employed in pharmacological research on Chinese herb, especially Chinese herbal formula [2–5], However, seropharmacology maintains some elusive issues, particularly the method of preparing drug-containing serum, which need to be intensively elucidated.
Hepatitis B virus (HBV) is a major affliction which burdens people globally . Currently, the approved therapies for HBV infection utilized in clinical setting consist mainly of alpha interferon  and nucleoside analogs, such as lamivudine  and entecavir (ETV) . However, these antiviral agents often give rise to undesirable adverse reactions and their efficacies are severely compromised in most patients by development of antiviral resistance after prolonged therapy. Therefore, there is an urgent need for the development of new anti-HBV agents that are both safe and effective.
San Huang Yi Gan Capsule (SHYGC) is a traditional Chinese herbal formula composed of the water soluble extracts of 6 medicinal plants, including Radix scutellariae, Rheum palmatum L., Radix bupleuri, Radix astragali, Fructus schizandrae and Radix glycyrrhizae. SHYGC shows remarkable potential of antiviral capability against HBV without appreciable side effects, and it significantly attenuates hepatitis B e antigen (HBeAg) level in the sera of patients with hepatitis B . However, the underlying mechanism for anti-HBV activity of SHYGC has so far remained unknown.
Here, we systemically addressed the methodology of preparation of drug-containing serum and looked insight into the mechanism underlying the anti-HBV capacity of SHYGC using the seropharmacological method. Moreover, a standardized model is to hopefully set up for the seropharmacological study on traditional Chinese medicine.
Drugs and reagents
San Huang Yi Gan Capsule (SHYGC) containing 1.67 g of the water soluble extracts of 6 Chinese herbs, provided by Institute for Chinese Materia Medica, Guangzhou University of Chinese Medicine, was dissolved in double distilled water (ddH2O) at 500 mg/ml. The authors are prepared to supply SHYGC to anyone who wants to replicate the study. Entecavir (ETV), derived from Bristol-Myers Squibb Corporate (New York, NY), was dissolved in 100% dimethyl sulfoxide at 10 μM as a stock. Prior to experimental tests, ETV was diluted in cell culture medium, with working concentration of 10 nM. 3H-dTTP was supplied by PerkinElmer NEN Inc. (Massachusetts, USA). All other reagents were commercially available.
Preparation of SHYGC-containing rabbit sera
All animal experiments were carried out in strict accordance with the China Experimental Animal Act 1988, and all animal research procedures were approved by the Research Ethics Committees of Guangzhou University of Chinese Medicine and Chengdu University of Traditional Chinese Medicine. New Zealand white rabbits weighing 2.0 ± 0.2 kg each were randomly arranged in 4 groups of 2 male and 2 female rabbits, and housed at one per cage in a ventilated, temperature- and humidity-controlled animal facility with 12 h light-12 h dark cycle, and fed with standard diet and distilled water ad libitum.
Rabbits of low, medium and high dose SHYGC groups were gavaged SHYGC in doses of 0.25 g/kg, 0.5 g/kg and 1.0 g/kg daily, while rabbits of vehicle group were gavaged the volume-matched ddH2O. Dose selection was based upon our previous study, in which SHYGC treatment significantly reduced HBeAg level in the sera of patients with hepatitis B . SHYGC of daily dosage was divided into equal shares and given to rabbits once, twice or thrice per day for 7 days. On day 8, after 12 h of fasting, rabbits were subject to last administration. At 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 3.5 h and 4 h post-administration, blood were retrieved from rabbits, via ear artery or transcardial puncture, with anesthesia by injection of pentobarbital sodium at a dose of 40 mg/kg in the marginal ear vein. Then, sera were collected by centrifugation of blood at 2000 × g for 10 min at 4°C, and some of sera were heat-inactivated at 56°C for 30 min. Finally, all of rabbit sera were sterilized by filtration through 0.22 μm cellulose ester membranes.
HepG2 2.2.15 cells culture and treatment
HepG2 2.2.15 cells were originally obtained from George Acs (Mount Sinai Medical Center, New York, N.Y.) and capable of constitutively producing and secreting HBV viral particles . The cells were seeded on 24-well plates at 5 × 104 cells per well and grown in 1 ml of minimal essential medium (MEM) supplemented with 10% fetal bovine serum, 380 μg of G418 per ml, 50U of penicillin per ml and 50 mg of streptomycin per ml in 5% CO2 atmosphere at 37°C. Forty eight hours post seeding, the cells approached 80% confluency and were treated for 9 days by 1 ml of MEM containing 2% fetal bovine serum, 380 μg of G418 per ml, 50U of penicillin per ml, 50 mg of streptomycin per ml, and 0.2 ml of SHYGC-containing rabbit sera, 0.2 ml of rabbit serum vehicle, or ETV at 10 nM. On day 10, the culture media conditioned by HepG2 2.2.15 cells were harvested and clarified by a 5-min centrifugation at 1000 × g at 4°C. The resultant supernatant media were processed for determination of hepatitis B surface antigen (HBsAg) expression, HBV DNA polymerase activity and HBV DNA level as below. Each test was performed in 8 wells in parallel.
Enzyme-linked immunosorbent assay of HBsAg expression
Fifty microliters of above HepG2 2.2.15 cells-conditioned media were added on 96-well plates coated with anti-HBs (antibody to HBsAg), and underwent the measurement of HBsAg expression with enzyme-linked immunosorbent assay (ELISA) kits (Yueliangwan Biotechnology Co., Shenzhen, China), as per the manufacturer's specifications. HBsAg level was expressed as the value of sample (P) against negative control (N), represented by the ratio of sample OD450nm (optical density at 450 nm) value to negative control OD450nm value.
Specific immunoprecipitation assay of HBV DNA polymerase activity
The HBV DNA polymerase (Pol) activity was sought in the above conditioned media by a minor modification of the specific immunoprecipitation method . Briefly, 400 μl of samples were placed into tubes of test and blank control. After excessive anti-HBs were added, mixtures were incubated at 37°C for 60 min, followed by two washes with Tris–HCl buffer (0.2 M, pH 7.5). In test tubes were added 20 μl of 1 mg/ml pronase E, 20 μl of 0.2 M Tris–HCl buffer (pH 7.5) containing 1.5% NP-40 and 0.4% β-mercaptoethanol, and 20 μl of substrate containing 0.08 M MgCl2, 0.24 M NH4Cl, 1 mM of dATP, dCTP and dGTP each and 0.5 μCi 3H-dTTP. In blank control tubes, 20 μl of above substrate and 40 μl of 0.2 M Tris–HCl buffer (pH 7.5) were added. After incubation at 37°C for 4 h, the reaction mixtures were spun, and 50 μl of supernatants were spotted on glass fiber filters and assayed for trichloroacetic acid-precipitable radioactivity by scintillation counting. CPM (counts per min) values for test tubes were obtained by subtraction of those for blank control tubes.
Dot blot hybridization assay of HBV DNA level
The detection of HBV DNA level in the above conditioned media was conducted with a non-radioactive dot blot hybridization assay (Xieheng Bioengineering Co., Shanghai, China), in light of the product handbook. Briefly, 50 μl of samples were applied to nitrocellu-lose membranes, followed by denaturation for 20 min. Then, the membranes were baked at 80°C for 1 h and prehybridized for 2 h at 42°C. After hybridization with digoxigenin-11-dUTP-labled probe DNA at 42°C for 24 h, the membranes were blocked by bovine serum albumin for 20 min at 42°C. The hybridized products were next detected by adding anti-digoxigenin-alkaline phosphatase antibody and the specified substrate. Blue-purple colors were precipitated in few minutes, and HBV DNA level was evaluated as percentage of the control.
Data obtained in this study were processed to determine means and standard errors, and presented as mean ± SEM (standard error of the mean). The statistical significances between the mean values were assessed by one-way analysis of variance (ANOVA) or Student’s t-Test with SPSS software. A value of P < 0.05 was considered statistically significant.
The methodology of preparing drug-containing serum
Given the same daily dosage, we wondered whether the administration regimen was a factor to affect the experimental result. Although all of medium dose SHYGC-containing rabbit sera reduced HBsAg expression, the potencies of drug-containing sera prepared by administration twice daily and thrice daily were higher than that of once per day. Additionally, no differences in the actions on HBsAg level were noted between twice daily and thrice daily (Figure 1B). In the following research, to facilitate the administration, rabbits received twice-a-day dosed treatment in the morning and at night to produce SHYGC-containing sera.
The approach of harvesting drug-containing sera from rabbits was then explored. Medium dose SHYGC-containing rabbit sera retrieved via ear artery and transcardial puncture both markedly lowered HBsAg expression, and drug-containing sera collected by these two methods revealed similar potency (Figure 1C). In the following experiments, for convenience of blood collection, drug-containing sera were harvested from rabbits via ear artery.
Finally, the optimal time point for collecting SHYGC-containing sera was determined. Medium dose SHYGC-containing sera harvested at all time points of 0.5 h to 4 h post-final administration displayed significant inhibition on HBsAg expression. While drug-containing sera collected at 2 h post-final administration exerted the strongest efficacy (Figure 1D). In the following assays, to obtain the highest potential of SHYGC, drug-containing sera were collected at 2 h post-final dose.
Consequently, an optimal and relatively standardized method was established to prepare drug-containing serum for seropharmacological research. In summary, drug of daily dosage was evenly divided into two portions and orally given to rabbits twice per day, in the morning and at night, for 7 consecutive days. On the 8th day, 2 h after the final administration, the rabbit sera was harvested via ear artery and subject to heat-inactivation at 56°C for 30 min. This comprehensive method of producing drug-containing serum was applied to all assays below.
SHYGC-containing sera inhibits HBsAg expression
SHYGC-containing sera inhibits HBV DNA Pol activity
SHYGC-containing sera inhibits HBV DNA replication
One of the most annoying problems for pharmacological study is that the data of in vitro experiment sometimes differs greatly from that of in vivo test. The reasons for this problem may include the poor absorption of drug in the digestive track, biotransformation of drug to active metabolite only in the body, inactivation of compound during metabolism, and indirect action of drug through release of internal factors, such as endogenous hormone, cell factor, antibody, complement, and so forth. For Chinese herb, conventionally in vitro pharmacological method is addition of the soluble extract of medicinal plant in its original pharmaceutics to in vitro test system, such as cells, tissues, viruses, organs, etc. However, some flaws of this type of research method are always concerned. First, the pharmaceutical constituents (chemical, ion, pH value, impurity and osmotic pressure) are bound to alter the experimental condition. Second, in the original pharmaceutics may be not the truly active component after internal biotransformation and metabolism. Third, the pharmacological data from this in vitro experimental system should be validated as false positive and false negative results are likely displayed. Efforts have been made in recent years to resolve these above concerns with seropharmacology, which is to perform pharmacological experiment in vitro with drug-containing animal serum, which retains the real metabolite after physical biotransformation, and reflects the drug absorption into blood stream, internal metabolism and indirect action through endogenous factors. Seropharmacology also precludes the interference of pharmaceutical constituents on experimental outcome and promote the reliability of research data. Furthermore, seropharmacology is more benefiting to the study on Chinese herb, especially the Chinese herbal formula, that generally features the characters of complex components, multiple targets and various functions. Taken together, seropharmacology provides a proper strategy and a novel approach to pharmacological research of Chinese medicine, and possibly western medicine as well, by bridging the experiments between in vitro and in vivo.
The most important issue for seropharmacology is the preparation of drug-containing animal serum which has been highly controversial since the emergence of seropharmacology. Attempts were made in this report to set up an optimally standardized method of preparing drug-containing serum. According to this method, the selection of animal to treat with drug was on the basis of the amount of blood the animal can provide. Rather than rats and mice, rabbits that can offer more blood were recruited to produce SHYGC-containing sera. In addition, the twice-a-day and thrice-a-day dosed medications were more potent than once-a-day dosed medication, which may be due to single dose of large amount of drug exceeding the capability of absorption in gastrointestinal tract. With this method, serum drug concentration seemed to reach the steady state (Css) after 7 consecutive days of administration, because all of medium dose SHYGC-containing sera obtained at various time points significantly lessened HBsAg expression, although the exact concentration of the herbal formula in rabbit sera was not measured, mainly due to the technical problem.
Nowadays, the main anti-HBV agents approved by World Health Organization are nucleoside analogs and costly alpha interferon, which commonly show poor effects on drug-resistant mutated HBV and cause adverse reactions and rebound of HBV following the cessation of medication. Nucleoside analogs, such as lamivudine and ETV, exert the function of anti-HBV, chiefly by inhibition of HBV DNA replication, while no direct action is clearly confirmed on the expression of HBsAg and HBeAg, which are indicative of HBV infection and multiplication respectively . Chinese herbs have been demonstrated recently to possess some advantages in the therapy of anti-HBV. For instance, HBeAg and HBV DNA are under negative seroconversions in chronic hepatitis B patients treated by Radix astragali, one of the herbs in SHYGC . Radix scutellariae, another herb of SHYGC, suppresses both wild-type HBV and lamivudine-resistant mutated HBV gene expression and virus production in human hepatoma cells . Based on our previous discovery that SHYGC is a potential anti-HBV agent by reducing HBeAg level in the sera of patients with hepatitis B, we showed that SHYGC dose-dependently diminished the expression of HBsAg, HBV DNA Pol activity and HBV DNA replication, which is in agreement with other reports on some herbs of SHYGC. For example, Radix astragali and Fructus schisandrae effectively blunt HBsAg expression in HepG2 2.2.15 cells and hepatocellular carcinoma cells respectively [15, 16]. Rheum palmatum L. inhibits HBV DNA replication and DNA Pol activity in HepG2 2.2.15 cells [17, 18]. Being a positive control, ETV, a guanosine nucleoside analogue with the activity against HBV reverse transcriptase, in this study drastically lowered HBV DNA replication and DNA Pol activity in HepG2 2.2.15 cells, consistent with previous reports [19–21], while no significant effect on HBsAg level was observed. In contrast, SHYGC presents a broad range of advantages by significantly suppressing the expressions of HBsAg and HBeAg, HBV DNA replication and DNA Pol activity, and it appears to be a promising candidate of HBV inhibitor in clinical practice. Concomitantly, seropharmacology was validated in our study to be applicable in pharmacological research of Chinese medicine.
Nevertheless, in this study inevitably remain some limitations, which should be under particular consideration. First, SHYGC concentration in rabbit sera was just assumed to attain the steady state (Css) at the time of collecting drug-containing sera, which was based on the principle of pharmacokinetics, in which serum drug concentration is gradually elevated to Css by multiple doses. Typically, if dosing interval is drug half-life (t1/2), the serum drug concentration will achieve Css in 5 to 7 t1/2 s. However, it is extremely difficult to obtain the exact t1/2 of SHYGC, that is composed of 6 Chinese herbs and a number of bioactive components with various t1/2 s, although the pharmacokinetics investigation of SHYGC would be supplementary to this study. On the other hand, Css is not essential for seropharmacological study, although the higher serum drug concentration is absolutely beneficial to the research. Second, in seropharmacological study including our research, healthy animals are commonly recruited to prepare drug-containing sera [1–5], but the animals with specific disease should be superior to healthy animals for this point, because the internal process of drug in animals with disease of interest is more close to that in human patients, and animals of disease model could differ significantly from healthy animals in the biotransformation and metabolism of drug, which may be a critical factor to influence the ingredients of drug-containing serum. However, there is a long way to go to establish various animal models of specific disease for seropharmacological research. Third, notwithstanding seropharmacology is a combination of in vivo and in vitro tests, it can not entirely represent the study in vivo, because the true effectiveness of drug in the body may be affected by other factors, such as the level of drug receptor in the body, the affinity of drug to receptor, the physical response to drug, etc.
Taken together, the antiviral property of SHYGC against HBV is strongly underpinned, which merits further investigation of the action mechanism and rigorously designed clinical trial in future. In this study, a relatively standardized model for seropharmacological research is established, and seropharmacology is shown to be a promising method for pharmacological study on drugs, in particular Chinese medicine. Combining with pharmacokinetics, seropharmacology can be broadly applied in biomedical research with bright prospect.
One-way analysis of variance
Steady state concentration
Hepatitis B e antigen
Hepatitis B surface antigen
Hepatitis B virus
Standard error of the mean
San Huang Yi Gan Capsule.
This work was supported by the Natural Science Foundation of Chengdu University of Traditional Chinese Medicine and the Science Foundation of Guangzhou University of Chinese Medicine.
- Bochu W, Liancai Z, Qi C: Primary study on the application of Serum Pharmacology in Chinese traditional medicine. Colloids Surf B Biointerfaces. 2005, 43 (3–4): 194-197.View ArticlePubMedGoogle Scholar
- Wu Q, Rong X, Huang P, Han J, Xu H: Study on inhibitory actions of san huang yi gan capsule (SHYGC) on HBeAg with seropharmacological method. Zhong Yao Cai. 2000, 23 (5): 275-278.PubMedGoogle Scholar
- Zhang YH, Liu JT, Wen BY, Liu N: Mechanisms of inhibiting proliferation of vascular smooth muscle cells by serum of rats treated with Dahuang Zhechong pill. J Ethnopharmacol. 2009, 124 (1): 125-129. 10.1016/j.jep.2009.04.012.View ArticlePubMedGoogle Scholar
- Zhang H, Xing WW, Li YS, Zhu Z, Wu JZ, Zhang QY, Zhang W, Qin LP: Effects of a traditional Chinese herbal preparation on osteoblasts and osteoclasts. Maturitas. 2008, 61 (4): 334-339. 10.1016/j.maturitas.2008.09.023.View ArticlePubMedGoogle Scholar
- Sun J, Bi Y, Guo L, Qi X, Zhang J, Li G, Tian G, Ren F, Li Z: Buyang Huanwu Decoction promotes growth and differentiation of neural progenitor cells: using a serum pharmacological method. J Ethnopharmacol. 2007, 113 (2): 199-203. 10.1016/j.jep.2007.05.018.View ArticlePubMedGoogle Scholar
- Kao JH: Molecular epidemiology of hepatitis B virus. Korean J Intern Med. 2011, 26 (3): 255-261. 10.3904/kjim.2011.26.3.255.View ArticlePubMedPubMed CentralGoogle Scholar
- Perrillo R: Benefits and risks of interferon therapy for hepatitis B. Hepatology. 2009, 49 (5 Suppl): S103-111.View ArticlePubMedGoogle Scholar
- Fung J, Lai CL, Seto WK, Yuen MF: Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. J Antimicrob Chemother. 2011, 66 (12): 2715-2725. 10.1093/jac/dkr388.View ArticlePubMedGoogle Scholar
- Cox N, Tillmann H: Emerging pipeline drugs for hepatitis B infection. Expert Opin Emerg Drugs. 2011, 16 (4): 713-729. 10.1517/14728214.2011.646260.View ArticlePubMedGoogle Scholar
- Sells MA, Chen ML, Acs G: Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci USA. 1987, 84 (4): 1005-1009. 10.1073/pnas.84.4.1005.View ArticlePubMedPubMed CentralGoogle Scholar
- Alexander GJ, Fagan EA, Rolando N, Guarner P, Callender ME, Eddleston AL, Williams R: Differential effect of ARA-AMP on serum DNA polymerase activity and serum HBV-DNA in chronic hepatitis B virus infection. A possible reason for lack of efficacy. J Hepatol. 1986, 3 (Suppl 2): S81-86.View ArticlePubMedGoogle Scholar
- Samal J, Kandpal M, Vivekanandan P: Molecular mechanisms underlying occult hepatitis B virus infection. Clin Microbiol Rev. 2012, 25 (1): 142-163. 10.1128/CMR.00018-11.View ArticlePubMedPubMed CentralGoogle Scholar
- Tang LL, Sheng JF, Xu CH, Liu KZ: Clinical and experimental effectiveness of Astragali compound in the treatment of chronic viral hepatitis B. J Int Med Res. 2009, 37 (3): 662-667. 10.1177/147323000903700308.View ArticlePubMedGoogle Scholar
- Tseng YP, Wu YC, Leu YL, Yeh SF, Chou CK: Scutellariae radix suppresses hepatitis B virus production in human hepatoma cells. Front Biosci (Elite Ed). 2010, 2: 1538-1547.Google Scholar
- Wang S, Li J, Huang H, Gao W, Zhuang C, Li B, Zhou P, Kong D: Anti-hepatitis B virus activities of astragaloside IV isolated from radix Astragali. Biol Pharm Bull. 2009, 32 (1): 132-135. 10.1248/bpb.32.132.View ArticlePubMedGoogle Scholar
- Loo WT, Cheung MN, Chow LW: Fructus schisandrae (Wuweizi)-containing compound inhibits secretion of HBsAg and HBeAg in hepatocellular carcinoma cell line. Biomed Pharmacother. 2007, 61 (9): 606-610. 10.1016/j.biopha.2007.08.023.View ArticlePubMedGoogle Scholar
- Li Z, Li LJ, Sun Y, Li J: Identification of natural compounds with anti-hepatitis B virus activity from Rheum palmatum L. ethanol extract. Chemotherapy. 2007, 53 (5): 320-326. 10.1159/000107690.View ArticlePubMedGoogle Scholar
- Kim TG, Kang SY, Jung KK, Kang JH, Lee E, Han HM, Kim SH: Antiviral activities of extracts isolated from Terminalis chebula Retz., Sanguisorba officinalis L., Rubus coreanus Miq. and Rheum palmatum L. against hepatitis B virus. Phytother Res. 2001, 15 (8): 718-720. 10.1002/ptr.832.View ArticlePubMedGoogle Scholar
- Levine S, Hernandez D, Yamanaka G, Zhang S, Rose R, Weinheimer S, Colonno RJ: Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother. 2002, 46 (8): 2525-2532. 10.1128/AAC.46.8.2525-2532.2002.View ArticlePubMedPubMed CentralGoogle Scholar
- Yamanaka G, Wilson T, Innaimo S, Bisacchi GS, Egli P, Rinehart JK, Zahler R, Colonno RJ: Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus. Antimicrob Agents Chemother. 1999, 43 (1): 190-193.PubMedPubMed CentralGoogle Scholar
- Innaimo SF, Seifer M, Bisacchi GS, Standring DN, Zahler R, Colonno RJ: Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother. 1997, 41 (7): 1444-1448.PubMedPubMed CentralGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6882/13/239/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.